Mustafa Abdo

MD | PhD| Pulmonologist | Principal Investigator at German Center for Lung Research & Airway Research Center North| 🇯🇴 🇩🇪

[Mustafa Abdo @respabdo]

Can we use Oscillometry to estimate COPD risk in young smokers?

Check our recent results in the #BlueJournal #ATS #COPD #smoking

[ATS Blue Journal @ATSBlueEditor]

High Oscillometry-derived Airway Resistance Is Associated with FEV1 Decline and Future Abnormal Spirometry in Smokers with Initially Normal Spirometry
@respabdo 
@atscommunity 

🔗 https://t.co/rvd2uutYMi

[World Allergy Organization @worldallergy]

#WAOJournal: Exploring trends and predictors of long-term #asthma #remission. Open Access. https://t.co/gKtdxa9E3i

[ATS Blue Journal @ATSBlueEditor]

Oscillometry-defined Small Airway Dysfunction in Tobacco-exposed Adults with Impaired or Preserved Airflow

Preserved airflow–small airway dysfunction: a pre-COPD phenotype diagnosed by oscillometry
@respabdo @atscommunity

🔓 Open Access

🔗 https://t.co/zSORuZ3ZSL

[NEJM Evidence @NEJMEvidence]

In this editorial, the authors discuss the importance of establishing a robust case definition of “young COPD” and the consequences of such a diagnosis. 🫁 Full editorial: https://t.co/9pU6iGzlHP

#Pulmonology

[NEJM Evidence @NEJMEvidence]

A Stats, STAT! video explains how restricted mean survival time summarizes survival from time 0 to a fixed, pre-specified period of follow-up. Watch now: https://t.co/bNH15GwlSK

[ATS Blue Journal @ATSBlueEditor]

Carcinogenic Industrial Air Emissions and Lung Cancer Risk in a Cohort of 440,000 Americans
@atscommunity

🔗 https://t.co/BYKsWQ29a4

[Mustafa Abdo @respabdo]

@khaledzeid An expiratory CT would be beautiful!

[ATS Blue Journal @ATSBlueEditor]

Is Achieving a Fully Race-Neutral Approach to Lung Function Classification Even Possible?

None of the commonly used spirometry outputs can simultaneously meet different definitions of race-neutrality
@suryapbhatt
@atscommunity

🔓 Open Access

🔗 https://t.co/CoteOHnyFC

[ATS Blue Journal @ATSBlueEditor]

Echocardiographic Endophenotypes of Chronic Obstructive Pulmonary Disease: A Step toward Personalized Medicine
@atscommunity

🔓 Open Access

🔗 https://t.co/Uj3bunafYi

[Mustafa Abdo @respabdo]

Check out our latest @ATSBlueEditor publication: Beyond the well-known HFpEF in COPD, we identify a COPD-specific LV dysfunction phenotype linked to reduced venous return and increased all-cause mortality 👇🏻

[ATS Blue Journal @ATSBlueEditor]

Characterization and Mortality Risk of Impaired Left Ventricular Filling in COPD

This analysis found that impaired left ventricular filling spikes all-cause mortality in COPD and uncovered two treatable traits
@respabdo

🔓Open Access

🔗 https://t.co/OyHTPrN2yF

[Frits Franssen @fritsfranssen]

Hard to comprehend and even harder to accept: a 46.3%, or 35 year (!), loss of life expectancy in the Gaza Strip during the period October, 2023, to September, 2024. Touched by this @TheLancet paper. https://t.co/UnBXjTluWM

[Mustafa Abdo @respabdo]

Glad to share exciting new findings from our recent study on IL-33 and its role in asthma and COPD, where we measured IL-33 levels in induced sputum using ultra-sensitive assay..

[ERS publications @ERSpublications]

ERJ: In patients with COPD, targeting IL-33 might be auspicious in former smokers. However, disease severity should also be considered. In patients with severe asthma, targeting IL-33 might be a potential treatment option, irrespective of T2-status. https://t.co/jbF9faDc30

[Mustafa Abdo @respabdo]

@SanjayResp @CFR_WA Congratulations mate 🎉

[Mustafa Abdo @respabdo]

How to improve post-COVID muscular dysfunction? Check this Impressive work by @Transparent_AC & @bnrgm

[ATS Blue Journal @ATSBlueEditor]

The Blue Journal thanks Binaya Regmi, MD, for his contribution to the September 1 issue

Improving Dyspnea after COVID-19 with Inspiratory Muscle Training
@Transparent_AC

https://t.co/UHEo9NLvj8

[Mustafa Abdo @respabdo]

@Transparent_AC @ATSBlueEditor @binrgm Impressive! Great job ! Congratulations 🎊

[Sanjay Ramakrishnan @SanjayResp]

Super fun co-chairing the @AstraZeneca EC global respiratory leadership forum alongside the #ERSCongress2024 in Vienna. Thank you everyone for making this a great success!

[Eric Topol @EricTopol]

A landmark paper on protein aging clocks, validated across 3 country biobanks (UK, FInland, China) for association with risk of 18 chronic diseases, mortality, and age-related traits such as cognitive decline
@NatureMedicine @austinargen and colleagues
https://t.co/ClHrHTRWbC

[ERS publications @ERSpublications]

Breathe: Imaging plays a vital role in asthma diagnosis and detection or exclusion of comorbidities. Further research is required to standardise the application of imaging in asthma and allied diseases. https://t.co/AD6dylCAHf

[ATS Blue Journal @ATSBlueEditor]

Can We Use Lung Function Thresholds and Respiratory Symptoms to Identify Pre-Chronic Obstructive Pulmonary Disease?

Pre-bronchodilator FEV1/FVC at the 10th percentile identifies those at risk of developing COPD in community settings

🔗 https://t.co/ysZqTOdcIP

[NEJM @NEJM]

Special Article: Implications of Race Adjustment in Lung-Function Equations https://t.co/uQ83ohdbbd

Editorial: Beyond Diagnostics — Removing Race from Lung-Function Test Interpretation https://t.co/DTrbUi2OeR

#ATS2024 @atscommunity